Virax Biolabs Group Ltd. has announced the closing of a $5 million private placement of its securities. The company sold and issued 12,500,000 ordinary shares (or equivalents) and preferred investment options to purchase up to 12,500,000 ordinary shares at a combined purchase price of $0.3999 per pre-funded warrant and accompanying preferred investment option. The pre-funded warrants have an exercise price of $0.0001 per share and do not expire, while the preferred investment options have an exercise price of $0.40 per ordinary share and are exercisable for five years from the effective date of the initial registration statement. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, was made in a private placement exempt from registration under the Securities Act. Virax intends to use the net proceeds for working capital, extending its cash runway into the first half of 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief on December 04, 2025, and is solely responsible for the information contained therein.
Comments